This trial is looking at a drug called brentuximab for people with Hodgkin lymphoma who are too unwell to have chemotherapy.
Doctors usually use chemotherapy to treat Hodgkin lymphoma (HL). But some people are too unwell to have this type of treatment, or have another medical condition which means they cannot have chemotherapy.
Researchers know that Brentuximab has been helpful for people whose HL has come back after chemotherapy treatment. So they think this drug may help people who can’t have chemotherapy. They also think it may have fewer side effects.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Professor John Radford |
| Sponsor: |
University of Birmingham |
| Funders: |
TAP Bloodwise |
| Disease Site: |
Hodgkin’s lymphoma |
| Trial Type: |
Clinical Trial of an Investigational Medicinal Product |
| Status: |
Follow-up |
| UKCRN Study ID: (if applicable) |
14703 |
| Open to new sites? |
No |
| Recruitment start date: |
Jan 2014 |
| Anticipated Recruitment end date |
Oct 2015 |
| CRCTU Trial Management Team: |
Haematology |
| Trial E-mail Address: |
BREVITY@trials.bham.ac.uk |